Systemic agents for mCRC consist of chemotherapy based on a fluoropyrimidine (5-FU), oxaliplatin, and irinotecan (in combination or in sequence) and monoclonal/targeted agents targeting BRAF mutation18–20, NTRK fusion oncoprotein21,22, vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) (in patients with RAS and BRAF wild-type tumors)23,24 as well as anti-programmed death-1 (PD-1)/ anti-programmed death ligand-1 (PD-L1) agents targeting patients with microsatellite instability-high (MSI-H) or with high tumor mutation burden16,17. This evidence concerns the gene BRAF and neoplasm.